Chemotherapy is ineffective in GIST [4, 5]; however, the development of targeted treatments in the form of tyrosine kinase inhibitors (TKIs) targeting KIT, PDGFR and BCR-ABL has dramatically improved outcomes for GIST patients over the past 20 years [6–8]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.